BridgeBio Pharma (BBIO) Net Equity Issued and Repurchased (2018 - 2024)

BridgeBio Pharma (BBIO) has 4 years of Net Equity Issued and Repurchased data on file, last reported at -$18000.0 in Q3 2024.

• For the quarter ending Q3 2024, Net Equity Issued and Repurchased fell 100.01% year-over-year to -$18000.0; the trailing twelve-month figure through Jun 2025 stood at -$18000.0 (down 100.0% YoY), and the FY2024 full-year result was $314.7 million, down 30.03% from the prior year.
• Net Equity Issued and Repurchased declined to -$18000.0 in Q3 2024, from $38.2 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $315.3 million in Q1 2024 to a low of -$454000.0 in Q4 2023.
• A 3-year average of $92.9 million and a median of $21.5 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased slumped 109.27% in 2023 and jumped 3594.0% in 2024, its largest moves.
• Tracing BBIO's Net Equity Issued and Repurchased over 3 years: stood at $4.9 million in 2022, then tumbled by 109.27% to -$454000.0 in 2023, then soared by 96.04% to -$18000.0 in 2024.
• Business Quant data shows BBIO's Net Equity Issued and Repurchased at -$18000.0 in Q3 2024, $38.2 million in Q2 2024, and $315.3 million in Q1 2024.